September 30, 2021

Session 1: Where Are We Now with DLBCL Therapy?

Current landscape of frontline DLBCL therapy
Ranjana H. Advani, Stanford Cancer Institute, Stanford, CA

Clinical trials in DLBCL: Ideal design meets clinical reality
Grzegorz S. Nowakowski, Mayo Clinic College of Medicine and Science, Rochester, MN

Panel Discussion

Moderator
Sonali M. Smith, University of Chicago, Chicago, IL

Panelists
Ranjana H. Advani
Grzegorz S. Nowakowski
Jeremy S. Abramson, Massachusetts General Hospital, Boston, MA
Brad S. Kahl, Washington University in St. Louis, St. Louis, MO
Judith Trotman, University of Sydney, Sydney, NSW, Australia
Wyndham H. Wilson, National Cancer Institute, Bethesda, MD

Session 2: DLBCL Heterogeneity: Beyond Cell of Origin

The use of DLBCL genetic subtypes to predict response to targeted therapies
Louis M. Staudt, National Cancer Institute, Bethesda, MA

Heterogeneity in tumor phenotype and microenvironment of DLBCL
Ash A. Alizadeh, Stanford University, Stanford, CA

Panel Discussion

Moderator
Ari M. Melnick, Weill Cornell Medical College, New York, NY
Panelists
Ash A. Alizadeh
Louis M. Staudt
Daniel Hodson, University of Cambridge, Cambridge, United Kingdom
Georg Lenz, University of Münster, Münster, Germany
David W. Scott, BC Cancer, Vancouver, BC, Canada
Margaret A. Shipp, Dana-Farber Cancer Institute, Boston, MA

October 1, 2021

Session 3: Opportunities for Targeted Therapies and Immunotherapies

Specific agents that primarily target the malignant cell
Georg Lenz, University of Münster, Münster, Germany

Naked and armed antibodies in DLBCL
Gilles Salles, Memorial Sloan Kettering Cancer Center, New York, NY

Activating the anti-tumor immune response using immune checkpoint blockade and bispecific antibodies
Stephen M. Ansell, Mayo Clinic College of Medicine and Science, Rochester, MN

Panel Discussion

Moderator
Louis M. Staudt, National Cancer Institute, Bethesda, MA

Panelists
Stephen M. Ansell
Georg Lenz
Gilles Salles
Martin Hutchings, Copenhagen University Hospital, Copenhagen, Denmark
Marcela V. Maus, Massachusetts General Hospital, Boston, MA
Jason Westin, The University of Texas MD Anderson Cancer Center, Houston, TX

Session 4: Trial Designs of the Future: Challenges and Opportunities

Key issues in DLBCL trial design - who is getting left behind?
Thomas E. Witzig, Mayo Clinic, Rochester, MN

Novel trial designs in diffuse large B-cell lymphoma
Mark Roschewski, National Cancer Institute, Bethesda, MD

Leveraging ctDNA for adapted trials in DLBCL
David M. Kurtz, Stanford University, Stanford, CA
Panel Discussion

Moderator
Wyndham H. Wilson, National Cancer Institute, Bethesda, MA

Panelists
David M. Kurtz
Mark Roschewski
Thomas E. Witzig
Sandra J. Horning, Stanford University School of Medicine, Stanford, CA
Laurie Sehn, BC Cancer, Vancouver, BC, Canada
Louis M. Staudt, National Cancer Institute, Bethesda, MA

Meeting Summary and Closing Remarks
Louis M. Staudt